Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2012. The report details a specific share repurchase transaction executed on February 17, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 495,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,428.5 pence per share; lowest price paid was 1,410.5 pence per share.
- Treasury Holdings (Settled): 503,067,927 shares (9.06% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,687,927 shares (9.99% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,050,458,348 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 495,000 shares on February 17, 2012. This transaction increased the proportion of shares held in Treasury to 9.99% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (503,067,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (9.99% held in Treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (5,050,458,348 shares in issue).
- Note that this filing does not contain operational or financial performance data for the period.